NCT06873269Recruiting
Holmium-166 Transarterial Radioembolization for the Treatment of Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 12 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to evaluate the effectiveness and safety of Holmium-166 (Ho-166) transarterial radioembolization (TARE) for treating patients with locally advanced hepatocellular carcinoma (HCC), a common type of liver cancer. HCC is often linked to conditions like liver cirrhosis and viral hepatitis, with a poor prognosis for advanced stages. TARE involves delivering radioactive particles directly to liver tumors, sparing healthy tissue and providing targeted radiation. This study will include patients diagnosed with HCC who have received Holmium-166 TARE treatment between January 2010 and December 2024. Researchers will look at patient and tumor characteristics, side effects, how well the treatment works, and survival outcomes. The goal is to determine whether Holmium-166 TARE is a safe and effective treatment option for people with locally advanced HCC. The findings will help doctors better understand how this therapy can be used to treat liver cancer and whether it can improve survival rates for patients with this challenging disease.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 21 Feb 2025
- Start date
- 1 Feb 2025
- Primary completion date
- 1 Feb 2026
- Lead sponsor
- Universitair Ziekenhuis Brussel
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06873269
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Feb 2025 to the primary completion date, 1 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- prior treatment with any of the following treatment modalities for HCC: systemic therapy, hepatic radiation therapy
- currently enrolled in clinical studies where patient receive investigational therapeutic drug
- concurrent malignancy
Other illness
- metastatic disease
- active contra-indications to angiography or selective catherization (i.e. severe vascular disease or bleeding diathesis)
- uncontrolled and/or severe comorbidities (active infection, heart failure,...) with limited estimated life expectancy
- history of or know allergic reactions to used compounds
Who the study is looking for
- aged 18 year or older
- diagnosed with locally advanced HCC without extra-hepatic metastases
- HCC must not be amendable to treatment by surgical resection or percutaneous radiofrequency ablation
- after assessment by the investigator and multidisciplinary tumor board, the patient is considered suitable for protocol treatment with Holmium-166 TARE
- ECOG performance status 0-2
- child-Pugh A-B
- tumor response evaluable with mRECIST criteria during follow-up
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UZ Brussel Coordinator of this site? Confirm its status | Brussels | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.